Broadcast Date:
- Time:
Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and manufacturability. While incremental improvements in cell line engineering and bioprocess modeling have driven progress, the rapid evolution of AI and digital tools is poised to reshape biopharmaceutical process development and manufacturing.
In this GEN webinar, Thibault Laurent, an expert in cell line development and genome engineering, shares a data-driven vision for the future of biologics production and discusses progress toward holistic optimal design of cell lines, genetic systems, and bioprocesses. He will discuss how Kernel, a software design tool that powers Asimov’s CHO Edge system, can accelerate timelines and improve titers for cell line and process development. The webinar will cover case studies that demonstrate how this system delivers high-titer clones (8–11 g/L) in less than four months for monoclonal and bispecific antibodies. Finally, he will discuss broader capabilities for integrating multi-omics and bioreactor-scale models to further optimize growth, productivity, and quality.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Director, Strategic Alliance
Asimov
